Intestinal fibrosis in inflammatory bowel disease: Progress in basic and clinical science

Current Opinion in Gastroenterology

Volumn 24, Issue 4, 2008, Pages 462-468

  Rieder, Florian ^a,b   Fiocchi, Claudio ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Fibroblast; Fibrosis; Inflammatory bowel disease; Stricture

Indexed keywords

ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; GALECTIN 3; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 21; OSTEOPONTIN; PLACEBO; TOLL LIKE RECEPTOR; TRANILAST; TRANSFORMING GROWTH FACTOR BETA1; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; WNT PROTEIN;

BALLOON DILATATION; CAPSULE ENDOSCOPY; CELL; CELL ACTIVATION; CELL FUNCTION; CELL TRANSFORMATION; CLINICAL TRIAL; COLITIS; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CROHN DISEASE; DOUBLE BALLOON ENTEROSCOPY; ENDOTHELIUM CELL; ENTERITIS; EPITHELIUM CELL; EXPERIMENTAL MODEL; FIBROBLAST; FIBROCYTE; HUMAN; INTESTINAL FIBROSIS; INTESTINE STENOSIS; MESENCHYME CELL; MYOFIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; RESTENOSIS; REVIEW; RISK ASSESSMENT; SEROLOGY; STENT;

FIBROBLASTS; FIBROSIS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;

EID: 67649784378     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282ff8b36     Document Type: Review

References (58)

1. Rieder F, Brenmoehl J, Leeb S, et al. Wound healing and fibrosis in intestinaldisease. Gut 2007; 56:130-139.
2. Burke JP, MulsowJJ, O'Keane C, et al. Fibrogenesis in Crohn's disease. Am JGastroenterol 2007; 102:439-448.
3. Meijer MJ, Mieremet-Ooms MA, van der Zon AM, et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007; 39:733-739.
4. Di Sabatino A, Pickard KM, Rampton D, et al. Blockade of transforming growth factor-β up-regulatesT-box transcription factorT-bet, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa. Gut 2008; 4 Janaury [Epub ahead of print].
5. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, et al. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 2007; 13:2960-2966.
6. Di Sabatino A, PenderSL, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by antitumor necrosis factor antibodies. Gastroenterology 2007; 133:137-149.
7. Monteleone G, Caruso R, Fina D, et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006; 55:1774-1780.
8. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13:1324-1332. 9 Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 2003; 124:1866-1878.
9. Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggersTGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 2007; 178:5859-5870.
10. Lippert E, Falk W, Bataille F, et al. Soluble galectin-3 is a strong, colonicepithelial-cell-derived, lamina propria fibroblast-stimulating factor. Gut 2007; 56:43-51.
11. Lawrance IC, Wu F, Leite AZ, et al. A murine model of chronic inflammationinduced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology 2003; 125:1750-1761.
12. Fichtner-Feigl S, Fuss IJ, Preiss JC, et al. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 2005; 115:3057-3071.
13. Wu F, Chakravarti S. Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. J Immunol 2007; 179:6988-7000.
14. Mori R, Shaw TJ, Martin P. Molecular mechanisms linking wound inflammationand fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 2008; 205:43-51.
15. Brack AS, Conboy MJ, Roy S, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 2007; 317:807-810.
16. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived me-senchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007; 87:858-870.
17. Pilling D, Roife D, Wang M, et al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 2007; 179:4035-4044.
18. Sakai N, Wada T, Yokoyama H, et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA 2006; 103:14098-14103.
19. Haudek SB, Xia Y, Huebener P, et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci USA 2006; 103:18284-18289.
20. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112:1776-1784.
21. Lee JM, DedharS, Kalluri R, et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172:973-981.
22. Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282:23337-23347.
23. Kaimori A, Potter J, Kaimori JY, et al.Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 2007; 282:22089-22101.
24. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res 2002; 90:1189-1196.
25. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to- mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13:952-961. 27 Wilm B, Ipenberg A, Hastie ND, et al. The serosal mesothelium is a major source of smooth muscle cells of the gut vasculature. Development 2005; 132:5317-5328.
26. Lund PK, Zuniga CC. Intestinal fibrosis in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol 2001; 17:318-323.
27. Vallance BA, Gunawan MI, Hewlett B, et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 2005; 289:G116-G128.
28. Motomura Y, Khan WI, El-Sharkawy RT, et al. Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1. Gut 2006; 55:662-670.
29. Armaka M, Apostolaki M, Jacques P, et al. Mesenchymal cell targeting byTNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008; 205:331 -337.
30. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006; 101:1030-1038.
31. Binion DG, Theriot KR, Shidham S, et al. Clinical factors contributing to rapid reoperation for Crohn's disease patients undergoing resection and/or strictureplasty. J Gastrointest Surg 2007; 11:1692-1698; discussion 1698.
32. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126:414-424.
33. Papp M, Altorjay I, Norman GL, et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis 2007; 13:984-992.
34. Papadakis KA, Yang H, Ippoliti A, et al. Antiflagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007; 13:524-530.
35. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56:1394-1403.
36. Erzin Y, Uzun H, Karatas A, et al. Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn's disease. J Gastroenterol Hepatol 2007; 27 August [Epub ahead of print].
37. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006; 101:360-367.
38. Spada C, Shah SK, Riccioni ME, et al. Video capsule endoscopy in patients with known or suspected small bowel stricture previously tested with the dissolving patency capsule. J Clin Gastroenterol 2007; 41:576-582.
39. Sun B, Shen R, Cheng S, et al. The role of double-balloon enteroscopy in diagnosis and management of incomplete small-bowel obstruction. Endoscopy 2007; 39:511 -515.
40. Fukumoto A, Tanaka S, Yamamoto H, et al. Diagnosis and treatment of small-bowel stricture by double balloon endoscopy. Gastrointest Endosc 2007; 66:S108-S112.
41. Higgins PD, Caoili E, Zimmermann M, et al. Computed tomographic enterography adds information to clinical management in small bowel Crohn's disease. Inflamm Bowel Dis 2007; 13:262-268.
42. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54:237-241.
43. Matsuhashi N, Nakajima A, Suzuki A, et al. Long-term outcome of nonsurgical strictureplasty using metallic stents for intestinal strictures in Crohn's disease. Gastrointest Endosc 2000; 51:343-345.
44. Ajlouni Y, Iser JH, Gibson PR. Endoscopic balloon dilatation of intestinal strictures in Crohn's disease: safe alternative to surgery. J Gastroenterol Hepatol 2007; 22:486-490.
45. Van Assche G. Intramural steroid injection and endoscopic dilation for Crohn's disease. Clin Gastroenterol Hepatol 2007; 5:1027-1028.
46. East JE, Brooker JC, Rutter MD, et al. A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn's strictures. ClinGastroenterol Hepatol 2007; 5:1065-1069.
47. Brooker JC, Beckett CG, Saunders BP, et al. Long-acting steroid injection after endoscopic dilation of anastomotic Crohn's strictures may improve the outcome: a retrospective case series. Endoscopy 2003; 35:333-337.
48. Singh VV, Draganov P, Valentine J. Efficacy and safety of endoscopic balloon dilation of symptomatic upper and lower gastrointestinal Crohn's disease strictures. J Clin Gastroenterol 2005; 39:284-290.
49. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
50. Sorrentino D, Terrosu G, Vadala S, et al. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease. Digestion 2007; 75:22-24.
51. Sorrentino D, Avellini C, Beltrami CA, et al. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 2006; 21:276-281.
52. Swaminath A, Lichtiger S. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. Inflamm Bowel Dis 2008; 14:213-216.
53. Keuchel M. Double balloon (push-and-pull) enteroscopy: breakthrough in the management of small intestinal strictures in Crohn's disease? Eur J Gastroenterol Hepatol 2007; 19:523-525.
54. Pohl J, May A, Nachbar L, et al. Diagnostic and therapeutic yield of push-and-pull enteroscopy for symptomatic small bowel Crohn's disease strictures. Eur J Gastroenterol Hepatol 2007; 19:529-534.
55. Koltun WA. Dangersassociated with endoscopic management ofstrictures in IBD. Inflamm Bowel Dis 2007; 13:359-361.
56. Kelly DJ, Zhang Y, Gow R, et al.Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 2004; 15:2619-2629.
57. Martin J, Kelly DJ, Mifsud SA, et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res 2005; 65:694-701.
58. Oshitani N, Yamagami H, Watanabe K, et al. Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease. Gut 2007; 56:599-600.